NEW YORK (GenomeWeb News) – BG Medicine today reported first quarter revenues of $739,000, down 17 percent from $888,000 in the first quarter of 2013.

Sales of the company's BGM-Galectin-3 heart failure test accounted for all of its revenues. It posted no service revenues in the quarter, compared to $68,000 in service revenues in Q1 2013.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: spatiotemporal study of lncRNA expression, role of extrachromosomal, circular DNAs in yeast, and more.

A European team has launched a four-year study to develop a test to gauge cervical, ovarian, uterine, or aggressive breast cancer risk in women.

As interest in personalized medicine grows, government contractors are entering the field, the Washington Post reports.

In PLOS this week: Plasmodium knowlesi population genetics, oral microbiome of infants and children, and more.